Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Active, not recruiting · NCT03773367 · Registry updated 2025-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | Resectable Gastric and Gastroesophageal Junction Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-09-10 | NCT03773367 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Lund University Hospital | 32 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centrallasarettet i Växjö | Vaxjo | Sweden | 1 |
| Karolinska University Hospital | Stockholm | Sweden | 10 |
| Lund University Hospital | Lund | Sweden | 3 |
| Oslo University Hospital, Ullevål hospital | Oslo | Norway | 3 |